Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on May 31, 2018. The report details a corporate action involving a reverse stock split of the Company's common stock, authorized by stockholders at the 2018 Annual Meeting held on May 30, 2018.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the structural change to the Company's capitalization.
Material Changes
- Reverse Stock Split: Effective 12:01 a.m. on June 1, 2018, twelve (12) shares of common stock were combined into one (1) share.
- Share Count Adjustment: The total number of outstanding shares was reduced by a factor of 12.
- Fractional Shares: No fractional shares were issued; holdings were rounded up to the next whole share.
- Trading Status: Common stock began trading on a split-adjusted basis on June 4, 2018, under the existing symbol "TROV."
Guidance, Outlook, and Risks
The filing contains no financial guidance, management commentary on future performance, or discussion of risks and contingencies beyond the execution of the stock split. The par value per share remains unchanged at $0.0001.
Investor Verification Checklist
- Verify the adjusted share count and price per share on the Company's subsequent 10-Q or 10-K filings.
- Confirm the trading symbol "TROV" and the effective trading date of June 4, 2018, with brokerage records.
- Review the press release (Exhibit 99.1) for any additional context regarding the rationale for the split.
- Check for any subsequent filings regarding the Company's liquidity status, as this 8-K does not disclose current cash positions.